Skip to main content
Log in

Immunosuppressive therapy of organ-specific nephritic autoimmune diseases with 15-deoxyspergualin

  • Immunoregulation
  • Published:
Agents and Actions Aims and scope Submit manuscript

Abstract

According to its immunopharmacological profile, 15-deoxyspergualin (15-DOS) has been investigated as to its disease-modifying activity on HgCl2-induced glomerulonephritis (GN) and on tubulointerstitial nephritis (TIN) in Brown-Norway rats. Both models are induced autoimmune disorders in which afflicted animals display high levels of serum autoantibodies directed against the glomerular or tubular basement membrane (GBM or TBM), respectively. The diseases are manifested by high serum creatinine and urea levels with severe proteinuria. In the model of HgCl2-GN, administration of 15-DOS clearly led to a reduction of proteinuria and decreased the amount of rat IgG attached to the GBM. Furthermore, a therapeutic effect could be demonstrated when 15-DOS was given after the appearance of clinical symptoms. Not only urine-protein values butalso anti-laminin antibodies returned to normal levels. Also in the experimental TIN-model, 15-DOS, either given during the induction phase, or even late in the onset of the disease, strongly prevented the proteinuria of this autoimmune disease and inhibited the formation of autoantibodies to TBN.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. H. U. Schorlemmer, G. Dickneite and F. R. Seiler,Treatment of acute rejection episodes and induction of tolerance in rat skin allotransplantation by 15-Deoxyspergualin. Transplant. Proc.22, 1626–1630 (1990).

    PubMed  Google Scholar 

  2. H. U. Schorlemmer and F. R. Seiler,15-Deoxyspergualin (15-DOS) for therapy in an animal model of multiple sclerosis (MS): Disease modifying activity on acute and chronic relapsing experimental allergic encephalomyelitis (EAE). Agents and Actions34, 156–160 (1991).

    Article  PubMed  Google Scholar 

  3. H. U. Schorlemmer, R. R. Bartlett and F. R. Seiler,Curative effects of 15-Deoxyspergualin on murine systemic lupus erythematosus-like disease in MRL/l autoimmune mice. Int. J. Immunotherapy7, 169–180 (1991).

    Google Scholar 

  4. H. U. Schorlemmer, R. R. Bartlett, R. Schleyerbach and F. R. Seiler,Immunosuppressive activity of 15-Deoxyspergualin (15-DOS) on various models of rheumatoid arthritis. Drugs Exp. Clin. Res.17, 471–483 (1991).

    PubMed  Google Scholar 

  5. N. Sato, K. Kamata and M. Okubo,Treatment of Heymann nephritis (HN) by 15-Deoxyspergualin. Kidney Int.33, 324–325 (1988).

    Google Scholar 

  6. P. G. Kerr, H. Y. Lan and R. C. Atkins,The effects of Deoxyspergualin on anti-GBM nephritis in rats. Kidney Int.38, 556–557 (1990).

    Google Scholar 

  7. C. Sapin, E. Druet, and P. Druet,Induction of antiglomerular basement membrane antibodies in the Brown-Norway rat by mercuric chloride. Clin. Exp. Immunol.28, 173–179 (1977).

    PubMed  Google Scholar 

  8. G. H. Thoenes, T. Sitter, K. H. Langer, R. R. Bartlett and R. Schleyerbach,Leflunomide (HWA 486) inhibits experimental autoimmune tubulointerstitial nephritis in rats. Int. J. Immunopharmac.11, 921–929 (1989).

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schorlemmer, H.U., Neubauer, H.P., Czech, J. et al. Immunosuppressive therapy of organ-specific nephritic autoimmune diseases with 15-deoxyspergualin. Agents and Actions 39 (Suppl 1), C121–C124 (1993). https://doi.org/10.1007/BF01972741

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01972741

Keywords

Navigation